SS-31 Research for Primary Mitochondrial Myopathy
An evidence-based overview of research examining SS-31 in the context of primary mitochondrial myopathy. This page synthesizes findings from peer-reviewed literature.
Research Summary
SS-31 has been evaluated in two Phase 3 trials (TAZPOWER, MMPOWER-3) for primary mitochondrial myopathy. While primary endpoints (6-minute walk test improvement) were not met, long-term extension data showed durable improvements in completers. The heterogeneous nature of PMM may complicate endpoint selection.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. SS-31 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.